Intrepid Automation, Inc. v. 3D Systems Corporation

District Court, S.D. California·Decided July 15, 2025·No. 3:24-cv-02262·Unknown

Opinion

INTREPID AUTOMATION, INC., Case No.: 24-cv-2262-AGS-DDL

Plaintiff, ORDER DENYING DEFENDANT’S v. MOTION TO DISMISS (ECF 26)

3D SYSTEMS, INC., et al.,

Defendants. This patent action opens another front in the years-long legal battle between two 3D-printing competitors—plaintiff Intrepid Automation, Inc., and defendant 3D Systems, Inc. Intrepid alleges that 3D Systems is infringing Intrepid’s Patent ’301 and Patent ’511.1 3D Systems moves to dismiss the complaint. DISCUSSION To survive 3D Systems’ motion to dismiss, Intrepid’s “complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” See Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quotation marks omitted). Plausibility requires more than mere “conclusions” or a “formulaic recitation” of elements; it must be based on “factual allegations” that “raise a right to relief above the speculative level.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007) (cleaned up). Even though the devices in patent cases can be complicated, the “pleading obligations are not onerous.” Bot M8 LLC v. Sony Corp. of Am., 4 F.4th 1342, 1354 (Fed. Cir. 2021). To “place the alleged infringer on notice of what activity is being accused of infringement,” id. at 1352, “an adequate complaint need only contain some factual allegations that, when taken as true, articulate why it is plausible that the accused product infringes the patent claim,” AlexSam, Inc. v. Aetna, Inc., 119 F.4th 27, 35 (Fed. Cir. 2024) (quotation marks omitted).

1 “Patent ’301” refers to U.S. Patent 11,014,301, and “Patent ’511” refers to According to 3D Systems, Intrepid’s complaint is deficient for each category of infringement—direct, willful, induced, and contributory. A. Direct Infringement Direct infringement comes in two flavors: (1) literal infringement—that is, when a “product” “literally infringe[s] upon the express terms of a patent claim,” and (2) infringement under the doctrine of equivalents, which is when “there is equivalence between the elements of the accused product or process and the claimed elements of the patented invention.” Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 21 (1997). Under the doctrine of equivalents, the “scope of a patent is not limited to its literal terms but instead embraces all equivalents to the claims described.” Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 535 U.S. 722, 732 (2002). Under either theory, 3D Systems contends that Intrepid’s complaint fails. As to literal infringement, 3D Systems makes three arguments. Perhaps its strongest point is that “the relevant 3D printing technology involves complex processing and software and therefore requires a level of detail that is missing from the Complaint.” (ECF 26, at 20.) It’s true that “the complexity of the technology, the materiality of any given element to practicing the asserted claim(s), and the nature of the allegedly infringing device” can heighten “[t]he level of detail required” at the pleading stage. Bot M8, 4 F.4th at 1353. But, even for such cutting-edge devices, Intrepid’s complaint meets that standard. The complaint places 3D Systems on notice of which products infringe the ’301 and ’511 Patents: the PSLA 270 and additional products that are “under development,” including a PSLA-270-related “large-format [digital-light-processing] printer” and another “Bioprinter.” (ECF 1, at 19–20, 27–30.) The complaint also describes the allegedly infringing technology within each product: the “image projection system with multiple projectors which project sub-images arranged in an array with overlapping sub-images to form a composite image”; “a display subsystem controlling the image projection system and each of the projectors”; and “digital filters [that] adjust sub-image properties and alignment, including an irradiance mask, gamma adjustment mask, warp correction filter, and a blending bar.” (Id. at 21; see also id. at 5–6.) As for the PSLA 270, the complaint even details that there are “two projectors projecting two side-by-side sub-images downward.” (Id. at 14.) These allegations allow 3D Systems to “know what [Intrepid’s] patents claim” and “what [Intrepid] asserts [the accused] systems do.” See K-Tech Telecomms., Inc. v. Time Warner Cable, Inc., 714 F.3d 1277, 1287 (Fed. Cir. 2013). So 3D Systems is “on notice of” the “complex[]” “activity [that] is being accused of infringement.” See Bot M8, 4 F.4th at 1353. In a related argument, 3D Systems maintains that there is no “fair notice” because the “complaint lacks factual support that the accused products meet each and every element of claim 1 of the asserted patents.” (ECF 26, at 17 (cleaned up).) “If even one” “is missing,” it insists, “there cannot be a finding of literal infringement.” (Id. at 18.) Not so. “A plaintiff is not required to plead infringement on an element-by-element basis.” Bot M8, 4 F.4th at 1352. At any rate, Intrepid offered fair notice of its literal-infringement claim by attaching the ’301 and ’511 Patents as well as the patent application for 3D Systems’ allegedly infringing Bioprinter (ECF 1-2; ECF 1-3; ECF 1-11); describing 3D Systems’ purportedly infringing products in detail, including photographs of its PSLA 270 3D printer and a diagram of its internal architecture (ECF 1, at 13–21; ECF 1-6); and claiming that “the PSLA 270 infringes each limitation of each Asserted Patent,” as do 3D Systems’ Bioprinter and its “large-format version of the PSLA 270” (ECF 1, at 19–21). See, e.g., Disc Disease Sols. Inc. v. VGH Sols., Inc., 888 F.3d 1256, 1260 (Fed. Cir. 2018) (upholding patent-infringement complaint that attached the “asserted patents”; identified the accused products “by name and by attaching photos of the product packaging”; and alleged that “the accused products meet ‘each and every element of at least one claim [of plaintiffs’ patents], either literally or equivalently’”). Finally, 3D Systems asserts that Intrepid’s claims about the “in development” products are too “vague.” (See ECF 26, at 21.) But, according to the complaint, a 3D Systems representative said that the PSLA 270 is only “the first of what will be a family of new projector-over-VAT printing systems.” (ECF 1, at 19.) And, if the PSLA 270 infringes, it’s reasonable to infer that the “family” of related products “under development” will as well—especially if, as alleged, that technological progeny “works the same way as the PSLA 270” with an expected “four or more image projectors pointing downward to a larger build platform located in or on a vat of resin.” (See id. at 19–20.) Those allegations might ultimately be wrong, but they are far from vague. At any rate, the missing details about the PSLA 270 and other allegedly under-development products are “not ascertainable without discovery,” and thus “should not bar [Intrepid’s] filing of a complaint.” See K- Tech, 714 F.3d at 1286. So Intrepid’s literal-infringement claims survive. Turning to Intrepid’s doctrine-of-equivalents allegations, 3D Systems insists that they are too “conclusory” to state a claim. (ECF 26, at 24.) But once a complaint adequately states literal-infringement claims, “a gene

Free access — add to your briefcase to read the full text and ask questions with AI

Intrepid Automation, Inc. v. 3D Systems Corporation, (S.D. Cal. 2025).

Intrepid Automation, Inc. v. 3D Systems Corporation (Intrepid Automation, Inc. v. 3D Systems Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Warner-Jenkinson Co. v. Hilton Davis Chemical Co.
520 U.S. 17 (Supreme Court, 1997)
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.
535 U.S. 722 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Bartlett v. Strickland
556 U.S. 1 (Supreme Court, 2009)
Disc Disease Solutions Inc. v. Vgh Solutions, Inc.
888 F.3d 1256 (Federal Circuit, 2018)
Eko Brands, LLC v. Adrian Rivera Maynez Enters.
946 F.3d 1367 (Federal Circuit, 2020)
Bayer Healthcare LLC v. Baxalta Inc.
989 F.3d 964 (Federal Circuit, 2021)
Bot M8 LLC v. Sony Corporation of America
4 F.4th 1342 (Federal Circuit, 2021)
R+L Carriers, Inc. v. DriverTech LLC
681 F.3d 1323 (Federal Circuit, 2012)
Alexsam, Inc. v. Aetna, Inc.
119 F.4th 27 (Federal Circuit, 2024)